Loirat Chantal, Saland Jeffrey, Bitzan Martin
Assistance publique-Hôpitaux de Paris, Hôpital Robert-Debré, Nephrology Department, 75019 Paris, France.
Presse Med. 2012 Mar;41(3 Pt 2):e115-35. doi: 10.1016/j.lpm.2011.11.013. Epub 2012 Jan 27.
2011 has been a special year for hemolytic uremic syndrome (HUS): on the one hand, the dramatic epidemic of Shiga toxin producing E. coli -associated HUS in Germany brought the disease to the attention of the general population, on the other hand it has been the year when eculizumab, the first complement blocker available for clinical practice, was demonstrated as the potential new standard of care for atypical HUS. Here we review the therapeutic options presently available for the various forms of hemolytic uremic syndrome and show how recent knowledge has changed the therapeutic approach and prognosis of atypical HUS.
2011年对溶血尿毒综合征（HUS）来说是特殊的一年：一方面，德国爆发的与产志贺毒素大肠杆菌相关的溶血尿毒综合征疫情引起了公众对该疾病的关注；另一方面，这一年也是可用于临床实践的首个补体阻滞剂依库珠单抗被证明可能成为非典型溶血尿毒综合征新治疗标准的一年。在此，我们回顾目前针对各种形式溶血尿毒综合征可用的治疗选择，并展示最新知识如何改变了非典型溶血尿毒综合征的治疗方法和预后。
